Toxoplasmosis Treatment Drugs Market Report 2026

The toxoplasmosis treatment drugs market size has grown strongly in recent years. It will grow from $3.49 billion in 2025 to $3.67 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to prevalence of toxoplasmosis infections, limited treatment options, growing awareness among healthcare providers, increased hospital pharmacy distribution, adoption of conventional drug formulations.

The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in precision medicine, rising investment in anti-parasitic drug R&D, expansion of online pharmacies, growing immunocompromised patient population, introduction of novel combination therapies. Major trends in the forecast period include increased research in anti-parasitic drug development, rising demand for combination therapies, growth in pediatric and immunocompromised patient treatments, expansion of hospital and online pharmacy distribution channels, development of oral and parenteral formulations.

The rising prevalence of toxoplasmosis infections is expected to drive the growth of the toxoplasmosis treatment drug market in the coming years. Toxoplasmosis is an infection caused by the protozoan parasite Toxoplasma gondii in humans and animals. The increasing number of infections fuels demand for drugs such as pyrimethamine, spiramycin, and leucovorin, which are used to treat specific types of toxoplasmosis, thereby boosting the market. For example, in February 2024, according to data from the UK Health Security Agency, a UK-based government organization, 54 confirmed cases of toxoplasmosis were reported in the second quarter of 2023, up from 37 cases in the same period of 2022. Consequently, the rising prevalence of toxoplasmosis is contributing to the expansion of the toxoplasmosis treatment drug market.

Key companies in the toxoplasmosis treatment drug market are focusing on strategic investments to strengthen their market position. Strategic investments involve allocating resources to achieve long-term goals such as gaining competitive advantage, entering new markets, or developing new technologies. For instance, in April 2023, ASTRA Therapeutics, a UK-based drug development company, secured CHF 150,000 ($173,787) in funding to advance therapies for parasitic diseases, including malaria, cryptosporidiosis, and toxoplasmosis, which affect millions globally and cause significant losses in livestock and agriculture.

In August 2023, Vyera Pharmaceuticals, LLC, a Switzerland-based pharmaceutical company, entered into an asset purchase agreement with Phoenixus AG for an undisclosed amount. Under this agreement, the companies planned to sell rights to Daraprim, a prescription drug containing pyrimethamine used to treat toxoplasmosis in combination with a sulfonamide, and Vecamyl, used for moderately severe to severe essential hypertension and some cases of malignant hypertension. Phoenixus AG is a Switzerland-based biopharmaceutical company.

Major companies operating in the toxoplasmosis treatment drugs market are Sanofi SA, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Ltd, Alvogen Group Inc, Manus Aktteva Biopharma LLP, Cadila Healthcare Limited, Aurobindo Pharma Limited, Cipla Inc, Torrent Pharmaceuticals Ltd, Intas Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd, Jubilant Life Sciences, Zydus Lifesciences Ltd, Hetero Drugs Limited, Strides Pharma Science Limited, Alkem Laboratories Limited.

North America was the largest region in the toxoplasmosis treatment drugs market in 2025. The regions covered in the toxoplasmosis treatment drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the toxoplasmosis treatment drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the toxoplasmosis treatment drugs market by increasing the cost of imported raw materials and active pharmaceutical ingredients, leading to higher production costs. The parenteral and oral drug segments, particularly in regions like North America and Europe that rely on global supply chains, are most affected. While tariffs have created cost pressures, they have also incentivized local manufacturing and domestic sourcing, potentially boosting regional production capabilities and innovation in combination therapies.

The toxoplasmosis treatment drugs market research report is one of a series of new reports that provides toxoplasmosis treatment drugs market statistics, including toxoplasmosis treatment drugs industry global market size, regional shares, competitors with a toxoplasmosis treatment drugs market share, detailed toxoplasmosis treatment drugs market segments, market trends and opportunities, and any further data you may need to thrive in the toxoplasmosis treatment drugs industry. This toxoplasmosis treatment drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Toxoplasmosis treatment drugs are medications used to manage infections caused by Toxoplasma gondii. They treat the parasitic infection that can result from exposure to cat feces or contaminated food.

The main drug classes in the toxoplasmosis treatment market include pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and others. Chronic toxoplasmosis refers to long-term infection caused by the Toxoplasma gondii parasite. These drugs are indicated for both chronic and acute toxoplasmosis infections. Administration routes include oral and parenteral, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The toxoplasmosis treatment drug market consists of sales of clindamycin and atovaquone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.